menu
    • menu
    [{"orgOrder":0,"company":"NovaBiotics Ltd","sponsor":"Agility Clinical | PSR Group B.V.","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Amino Acid","year":"2016","type":"Inapplicable","leadProduct":"Cysteamine Bitartrate","moa":"Cystine","graph1":"Genetic Disease","graph2":"Phase II","graph3":"NovaBiotics Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NovaBiotics Ltd \/ Agility Clinical | PSR Group B.V.","highestDevelopmentStatusID":"8","companyTruncated":"NovaBiotics Ltd \/ Agility Clinical | PSR Group B.V."},{"orgOrder":0,"company":"NovaBiotics Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Np339","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"NovaBiotics Ltd","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NovaBiotics Ltd \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"NovaBiotics Ltd \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by NovaBiotics Ltd

    Menu

    NovaBiotics Ltd

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            NovaBiotics Ltd

                            United Kingdom arrow
                            OTS 2025
                            Not Confirmed

                            NovaBiotics Ltd

                            United Kingdom arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Np339

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            NovaBiotics to Present Preclinical Data on NP339 and Sponsor Symposium on New Antifungals at Upcoming 10th Con...

                            Details : NP339 as a novel peptide therapy candidate for invasive and respiratory fungal disease. NP339 has rapid, fungicidal activity against a broad range of clinically relevant pathogens.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            October 05, 2021

                            Lead Product(s) : Np339

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            NovaBiotics Ltd

                            United Kingdom arrow
                            OTS 2025
                            Not Confirmed

                            NovaBiotics Ltd

                            United Kingdom arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cysteamine Bitartrate

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase II

                            Sponsor : Agility Clinical | PSR Group B.V.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of the Dosing, Efficacy, and Safety of Oral Cysteamine in Adult Patients With Cystic Fibrosis Exacerba...

                            Details : Cysteamine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Cystic Fibrosis.

                            Product Name : Undisclosed

                            Product Type : Amino Acid

                            Upfront Cash : Inapplicable

                            December 22, 2016

                            Lead Product(s) : Cysteamine Bitartrate

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase II

                            Sponsor : Agility Clinical | PSR Group B.V.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth